New hope for Parkinson's freezing: drug targets brain chemical to improve walking
NCT ID NCT07316296
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests whether atomoxetine, a medication that affects the brain chemical noradrenaline, can reduce freezing of gait in people with Parkinson's disease. Sixty participants will receive either atomoxetine or a placebo and will complete walking tests, MRI scans, and questionnaires. The goal is to see if the drug can help people walk more smoothly and improve their quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboudumc
RECRUITINGNijmegen, Gelderland, 6525 GA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.